Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544935 | 1.00 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14536870 | 1.00 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9233678 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790006 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13495833 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL24503471 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL1108300 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14477868 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8573691 | 0.91 | SRD5A2 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL10000653 | 0.91 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414378-B1 | SEPARATION OF 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-5760045-A | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0646007-B1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5510351-A | PREGNANE ENZYME INHIBITOR FOR TREATING SKIN DISORDER, BALDNESS, PROSTATIC CANCER | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0646007-A4 | — | — | 1995-04-26 | — | — | EP | disclosed |
| EP-0646007-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023050-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | NR5A1, SRD5A2, CYP19A1 | SRD5A1 4/4885SRD5A2 2/4885LMNA 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.